The role of hepcidin as a biomarker for iron status in patients with chronic kidney disease (stage IV and V) with negative virology

Abstract

nemia is a severe complication of chronic kidney disease (CKD) that is seen in more than 80% of patients with impaired renal function. Hepcidin, an acute phase reactant protein produced in the liver,is a key regulator of iron homeostasis. We assessed hepcidin level in 45 non-dialysis patients (CKD stage IV and V with negative virology) and its relation to iron parameters. We found that that the mean of age 54.60±8.04, also male 75.6% and female 24.4% of sex. Regarding aetiology of renal disease, NSAIDS use was in 13 (28.9%), DM was in 11 (24.4%), HTN was in 17 (37.8%) and Stones former was in 4 (8.9%); regarding comorbidities, cancer was in 7 (15.6%), DM was in 6 (13.3%), HTN was in 12 (26.7%) and IHD was in 2 (4.4%). Mean Hb was 8.93±2.74. ESR was 50.88±15.09; Iron was 38.13±18.78; TIBC was 255.80±71.76; Ferritin was 358.27±109.57; Serum hepcidin was 23.43±12.46 and CRP was 8.91±6.48. In our study, 33.3% (n = 15) and 66.7% (n = 30) of the study population belonged to stage-4 and stage-5 CKD, respectively.